Tuesday, January 29th, 2013, 9:30-10:25am
Over the past 12 months, Takeda has acquired five diverse biopharma companies as it looks to enhance its global footprint. How do the additions of several marketed and pipeline drugs amplify Takeda’s portfolio and how has management integrated with these new entities? Join us for a fireside chat with a senior business development executive from Takeda to learn about the deal-making details, how these acquisitions play into Takeda’s global strategy, and what Takeda has in store for 2013 and beyond.
- David Low, Managing Director, Lazard & Co.
- Ken Araki, Vice President, Corporate Development, Global Business Development, Takeda Pharmaceutical Company
Vice President, Corporate Development, Global Business Development, Takeda Pharmaceutical Company
Since January 2012, Ken Araki has been in charge of managing Takeda’s global corporate development activities, including M&A and the Japan Business Development Group in charge of Japan/North Asia local transactions and global discovery research collaborations.
Managing Director, Lazard & Co.
David Low joined Lazard's Life Sciences Group in 2002 as a Managing Director based in San Francisco. Mr. Low has had a long career in Biotech M&A, advising on transactions including Roche’s restructuring of its Genentech ownership (1995 and 1999/2000), Johnson & Johnson’s acquisition of Centocor(1999) and Gilead’s acquisition of Myogen(2006), among others. On the financing side, Mr. Low has extensive experience with debt and equity, convertibles, R&D financings, private placements and royalty transactions for biotech companies.
Prior to joining Lazard, Mr. Low worked at Lehman Brothers from 1987 to 1996 and JP Morgan from 1996 through July 2002.
Harvard College, B.A., Johns Hopkins University, M.A. in International Economics, Yale University, M.B.A.